Beijing Xingwang Pharmaceutical

Beijing Xingwang Pharmaceutical is a clinical-stage biopharmaceutical company based in Beijing, China, specializing in the discovery and development of innovative small molecule therapeutics. The company primarily focuses on oncology and autoimmune disorders, with a robust pipeline centered on next-generation kinase inhibitors. Its lead candidate, XW10172, is a highly selective, irreversible Bruton tyrosine kinase (BTK) inhibitor currently being evaluated in clinical trials for B-cell malignancies and potentially autoimmune conditions. Xingwang Pharmaceutical aims to address unmet medical needs by optimizing the safety and efficacy profiles of established drug classes through advanced medicinal chemistry.